stockrowADC Therapeutics SA
ADCT Healthcare Drug Manufacturers Specialty & Generic
ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024.
- Revenue
- +2.17%
- EPS
- +78.0%
- Free cash flow
- +51.0%
- Total debt
- +1.87%
Quarter to June 2026, against a year earlier
Follow ADCT
Alert me
ADC Therapeutics SA (ADCT) EV/Sales
As of 5 November 2026, ADC Therapeutics SA (ADCT) trades at a EV/Sales of 1.9×. Over the past ten years it has ranged from −1.3× (November 2023) to 33.9× (December 2021); the current reading is higher than 64% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.7× | 274.12% |
| FY2024 | 1.0× | — |
| FY2023 | −0.2× | — |
| FY2022 | 0.4× | (98.93%) |
| FY2021 | 33.9× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.8× | (86.37%) |
| Mar 2026 | 5.8× | 57.09% |
| Dec 2025 | 3.7× | (36.49%) |
| Sep 2025 | 5.9× | 167.64% |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BIOA BioAge Labs, Inc. compare | −7.2× |
| AKBA Akebia Therapeutics, Inc. compare | 0.1× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| CGC Canopy Growth Corporation compare | 1.0× |
| GLAS Glass House Brands Inc. compare | 1.4× |
| ADCT ADC Therapeutics SA | 1.9× |
| ANIK Anika Therapeutics Inc. compare | 2.0× |
| LFCR Lifecore Biomedical, Inc. compare | 3.6× |
| SIGA Siga Technologies Inc. compare | 4.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)